Biosimilar

 

Humira

(Adalimumab)

Enbrel

(Etanercept)

Remicade

(Infliximab)

Rituxan

(Rituximab)

Avastin

(Bevacizumab)

Herceptin

(Trastuzumab)

Neulasta

(Pegfilgrastim)

Neupogen (Filgrastim)

Epogen

(Epoetin alfa)

Amgen

Approved

(Sep 2016)

Phase III

(Oct 2016)

Phase III

(May 2016)

Filed

(Dec 2016)

Pfizer

Phase III

(Top-line results released in Jan 2017)

Phase III

(Sep 2014)

Phase III

(Feb 2015)

Phase III

(Feb 2014)

Phase I

Approved

(Jun 2010)

(Hospira)

Approved

(Dec 2007)

(Hospira)

Sandoz

Will file in 1H17

Filed

(Dec 2015)

(Acquired EEA rights from Pfizer in Feb 2016)

Will file in 1H17

Filed

(May 2016)

Filed

(Mar 2016)

Approved

(Feb 2009)

Approved

(Aug 2007)

Mylan/ Biocon

Phase III

(May 2015)

Phase I

Pre-clinical

Phase III

Filed

(Aug 2016)

Filed

(Jul 2016)

Phase I

Samsung Bioepis

Filed

(Jul 2016)

Launched

(Feb 2016)

Launched

(Aug 2016)

Phase III

(Mar 2015)

Filed

(Oct 2016)

Celltrion

Pre-clinical

Pre-clinical

Launched

(Feb 2015)

Approved

(Feb 2017)

Pre-clinical

Filed

(Nov 2016)

Coherus

Will file in 2017

Will file in 1H17

Filed

(Nov 2016)

Boehringer Ingelheim

Filed

(Jan 2017)

Will file in 4Q17

Eli Lilly

 

資料來源: 各公司網站、EMA、Citi Research、筆者自行整理

喜歡這篇文章嗎?立即分享

你可能感興趣的文章